Laryngeal muscle surface receptors identified using random phage library

Laryngoscope

Volumn 115, Issue 11, 2005, Pages 1930-1937

  Flint, Paul W ^a,b   Li, Zhao Bo ^a   Lehar, Mohamed ^a   Saito, Koichiro ^a   Pai, Sara I ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Larynx; Muscle; Peptide; Phage display; Targeting

Indexed keywords

ADENOVIRUS VECTOR; ASPARAGYLPROLYLSERYLGLUTAMYLVALYLLYSYLHISTIDINE; CELL SURFACE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TYROSYLALANYLSERYLTHREONYLASPARAGYLPROLYLMETHIONINE; UNCLASSIFIED DRUG; PEPTIDE LIBRARY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DNA MODIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; LARYNX MUSCLE; MOUSE; MUSCLE CELL; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SKELETAL MUSCLE; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; BACTERIOPHAGE; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; GENE THERAPY; GENE VECTOR; IN VITRO STUDY; METABOLISM; METHODOLOGY; SPRAGUE DAWLEY RAT; VIROLOGY;

ADENOVIRIDAE; ANIMALS; BACTERIOPHAGES; CELL LINE; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; LARYNGEAL MUSCLES; MICE; MUSCLE, SKELETAL; PEPTIDE LIBRARY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE;

EID: 33644673385     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000172273.98418.8d     Document Type: Article

References (45)

1. Shiotani A, O'Malley Jr BWColeman ME, et al. Reinnervation of motor endplatesand increased muscle fiber size after hIGF-I gene transfer into the paralyzedlarynx. Hum Gene Ther 1998;3:2039-2047.
2. Flint PW, Shiotani A, O'Malley BW Jr. Gene transfer into denervated rat laryngeal muscle. Arch Otol HNS 1999;125:274-279.
3. Shiotani A, Jukumura M, Maeda M, et al. Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector. Gene Ther 2001;8:1043-1050.
4. Saito K, Shiotani A, Watabe K, et al. Adenoviral GDNF gene transfer prevents motoneuron loss in the nucleus ambiguus. Brain Res 2003;962:61-67.
5. Flint PW, Nakagawa H, Shiotani A, et al. Effects of insulin-like growth factor-1 gene transfer on myosin heavy chains in denervated rat laryngeal muscle. Laryngoscope 2004;114:368-371.
6. Nakagawa H, Shiotani A, O'Malley Jr BW, et al. Timing of human insulin-like growth factor-1 gene transfer in reinnervating laryngeal muscle. Laryngoscope 2004;114:726-732.
7. Hanta D, Akaaboune M, Lagord C, et al. Beneficial effects of insulin-like growth factor-I on wobbler mouse motor neuron disease. J Neurol Sci 1995;129(Suppl):122-126.
8. Vergani L, Finco C, Di Giulio,AM, et al. Effects of low doses of glycosaminoglycans and insulin-like growth factor-I on motor neuron disease in wobbler mouse. Neurosci Lett 1997;228:41-44.
9. Hemmi S, Geertsen R, Mezzacasa A, et al. The presence of human Coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998;9:2363-2373.
10. Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998;58:5738-5748.
11. Li D, Duan L, Freimuth P, O'Malley Jr BW. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999;45:4175-4181.
12. Li Y, Pong RC, Bergelson Jm, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999;59:325-330.
13. Bouri K, Feero WG, Myerburg MM, et al. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 1999;10:1633-1640.
14. Samoylova TI, Smith BF. Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve 1999;22:460-466.
15. Asaoka K, Tada M, Sawamura Y, et al. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 2000;92(6):1002-1008.
16. Welsh MJ, Smith AE, Zabner J, et al. Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium. Hum Gene Ther 1994;5:209-219.
17. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E-1 deleted adenovirus for gene therapy. Proc Natl Acad Sci 1994;91:4407-4411.
18. Work LM, Nicklin SA, Brain NJR, et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 2004;9:198-208.
19. Work LM, Ritchie N, Nicklin SA, et al. Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. Gene Ther 2004;11:1296-1300.
20. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 1996;2:299-305.
21. Pasqualini R, Rousalahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-366.
22. Nicklin SA, White SJ, Watkins SJ, et al. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000;102:231-237.
23. Engelhardt JF, Ye X, Doranz B, Wilson, JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci 1994;91:6196-6200.
24. Vitadello M, Shiaffino MV, Picard A, et al. Gene transfer in regenerating muscle. Hum Gene Ther 1994;5:11-18.
25. Wang Q, Finer, MH. Second generation adenovirus vectors. Nat Med 1996;2:714-716.
26. Petrof BJ, Acsadi G, Jani A, et al. Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. Am J Respir Cell Mol Biol 1995;13:508-517.
27. Haase G, Pettmann B, Vigne E, et al. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action. J Neurol Sci 1998;160(Suppl 1):S97-S105.
28. Haase G, Kennel P, Pettmann B, et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 1997;3:429-436.
29. Coleman ME, DeMayo F, Yin KC, et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 1995;270:12109-12116.
30. Alila H, Coleman M, Nitta H, et al. Expression of biologically active human insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats. Hum Gene Ther 1997;8:1785-1795.
31. Hauser MA, Robinson Ann, Hartigan-O'Connor, D, et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther 2000;2:16-25.
32. Shield MA, Haugen HS, Clegg CH, Hauschka SD. E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic mice. Mol Cell Biol 1996;16:5058-5068.
33. Li ZB, Lehar M, Flint PW. Identification of proteins associated with denervation muscle atrophy in the paralyzed larynx. Abstract in the Proceedings of the American Academy of Otolaryngology-Head Neck Surgery Annual Meeting, September 19-22, 2004, New York, NY.
34. Michael SI, Hong JS, Curiel DT, Engler JA. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 1995;2:660-668.
35. Magnusson MK, Hong SS, Boulanger P, Lindholm L. Genetic retargeting of adenovirus: novel strategy employing "deknobbing" of the fiber. J Virol 2001;75:7280-7289.
36. Thirion C, Larochelle N, Volpers C, et al. Strategies for muscle-specific targeting of adenoviral gene transfer vectors. Neuromusc Disord 2002;12:S30-S39.
37. SamoylovaT, Petrenko VA, Morrison NE, et al. Phage probes for malignant glial cells. Mol Cancer Ther 2003;2:1129-1137.
38. Work LM, Nicklin SA, White SJ, Baker AH. Use of phage display to identify novel peptides for targeted gene therapy. Methods Enzymol 2002;346:157-176.
39. Shiotani A, Flint, PW. Myosin heavy chain composition in rat laryngeal muscles after denervation. Laryngoscope 1998;108:1225-1229.
40. Bobinac D, Malnar-Dragojevic D, Bajek S, et al. Muscle fiber type composition and morphometric properties of denervated rat extensor digitorum longus muscle. Croat Med J 2000;41:294-297.
41. Takekura H, Kasuga N, Kitada K, Yoshioka T. Morphological changes in the triads and sarcoplasmic reticulum o frat slow and fast muscle fibres following denervation and immobilization. J Muscle Res Cell Motil 1996;17:391-400.
42. DelGaudio JM, Sciote JJ, Carroll WR, Esclamado RM. Atypical myosin heavy chain in rat laryngeal muscle. Ann Otol Rhinol Laryngol 1995;104:237-45.
43. Gunderson K, Maehlen J. Nerve-evoked electrical activity regulates molecules and cells with immunological function in rat muscle tissue. Eur J Neurosci 1994;6:1113-1118.
44. Englund P, Nennesmo I, Klareskog L, Lundberg IE. Inerleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002;46:1044-1055.
45. Wiendl H, Mitsdoerffer M, Schneider D, Muscle fibers and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003;125:1026-1035.